Overview

Study of Rifaximin in Minimal Hepatic Encephalopathy

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Rifaximin therapy will improve brain functioning on MRI scanning and change the microbiome and metabolome.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hunter Holmes Mcguire Veteran Affairs Medical Center
Collaborators:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Treatments:
Rifamycins
Rifaximin